Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 6/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559815 | 0.82 | VCAM1 (0.48) | TRPV4MAOBMAOAIDO1SLC1A5 | |
| SCHEMBL30224701 | 0.82 | VCAM1 (0.48) | TRPV4MAOBMAOAIDO1SLC1A5 | |
| SCHEMBL28481552 | 0.79 | CYP11B2 (0.50) | TRPV4ARCYP11B2CYP11B1 | |
| SCHEMBL1395661 | 0.78 | MAOB (0.61) | MAOBMAOACYP11B2SLC1A5CYP11B1 | |
| SCHEMBL30475151 | 0.78 | MAOB (0.61) | MAOBMAOACYP11B2SLC1A5CYP11B1 | |
| SCHEMBL2650513 | 0.78 | CYP11B2 (0.52) | TRPV4ARCYP11B2SLC22A12CYP11B1 | |
| SCHEMBL7022727 | 0.77 | ALDH1A1 (0.36) | TRPV4 | |
| SCHEMBL410587 | 0.77 | TRPV4 (0.57) | TRPV4MAOBMAOAARCYP11B2 | |
| SCHEMBL1343170 | 0.76 | MAOB (0.48) | TRPV4MAOBMAOACYP11B2SLC1A5 | |
| SCHEMBL101711 | 0.76 | TRPV4 (0.61) | TRPV4MAOBMAOAARCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | ORION CORPORATION (FI) | 2026-03-24 | — | — | US | claimed |
| CN-120192300-A | Method for preparing androgen receptor antagonist and intermediate thereof | 奥赖恩公司 | 2025-06-24 | — | — | CN | claimed |
| CN-119977836-A | Synthesis method of 2-chloro-4-bromobenzene | 太仓运通新材料科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-115605470-B | Method for preparing androgen receptor antagonist and intermediate thereof | 奥赖恩公司 | 2025-04-18 | — | — | CN | claimed |
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2023-06-08 | — | — | US | claimed |
| EP-4149938-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | Orion Corporation (FI) | 2023-03-22 | — | — | EP | claimed |
| CN-115605470-A | Process for preparing androgen receptor antagonists and intermediates thereof | 奥赖恩公司（FI） | 2023-01-13 | — | — | CN | claimed |
| WO-2021229145-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | claimed |
| CN-107428695-B | Process for preparing androgen receptor antagonists and intermediates thereof | 奥赖恩公司 | 2021-03-16 | — | — | CN | claimed |
| EP-3280710-B1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORP (FI) | 2020-02-26 | — | — | EP | claimed |
| US-10189789-B2 | Process for the preparation of androgen receptor antagonists and intermediates thereof | ORION CORPORATION (FI) | 2019-01-29 | — | — | US | claimed |
| US-20180099938-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2018-04-12 | — | — | US | claimed |
| EP-3280710-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | Orion Corporation (FI) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162604-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2016-10-13 | — | — | WO | claimed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-121949153-A | Synthesis method of 4-acetyl-2-chlorobenzonitrile and arylpyrazole compound | 曲靖师范学院 | 2026-05-01 | — | — | CN | disclosed |
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | ORION CORPORATION (FI) | 2026-03-24 | — | — | US | disclosed |
| WO-1998005642-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-02-12 | — | — | WO | disclosed |
| EP-0659047-A1 | HERBICIDAL BENZENE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005153-A1 | HERBICIDAL BENZENE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | AR, GNRHR, FSHR | TRPV4 776/4885MAOB 775/4885MAOA 586/4885 |
| US-20180099938-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | AR, NR5A1, GNRHR | TRPV4 475/4885MAOB 2397/4885MAOA 1750/4885 |
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | AR, FSHR, PKD1 | TRPV4 120/4885MAOB 1494/4885MAOA 1864/4885 |
| US-10189789-B2 | Process for the preparation of androgen receptor antagonists and intermediates thereof | AR, NR5A1, GNRHR | TRPV4 475/4885MAOB 2397/4885MAOA 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.